Canonica, G., Blasi, F., Crimi, N., Paggiaro, P., Papi, A., Fanelli, F., . . . Furneri, G. (2020). PRS50 Defining Type 2 Asthma and Patients Eligible to Dupilumab in Italy: A Biomarker-Based Analysis. Value in health, 23, S726. https://doi.org/10.1016/j.jval.2020.08.1930
Chicago-Zitierstil (17. Ausg.)Canonica, G.W, F. Blasi, N. Crimi, P. Paggiaro, A. Papi, F. Fanelli, A. Stassaldi, A. Serra, und G. Furneri. "PRS50 Defining Type 2 Asthma and Patients Eligible to Dupilumab in Italy: A Biomarker-Based Analysis." Value in Health 23 (2020): S726. https://doi.org/10.1016/j.jval.2020.08.1930.
MLA-Zitierstil (9. Ausg.)Canonica, G.W, et al. "PRS50 Defining Type 2 Asthma and Patients Eligible to Dupilumab in Italy: A Biomarker-Based Analysis." Value in Health, vol. 23, 2020, p. S726, https://doi.org/10.1016/j.jval.2020.08.1930.